Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-201 in Advanced Clear Cell Renal Cell Carcinoma
NCT06708936Phase 1Withdrawn
- Sponsor
- Kousai Bio
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSD-201 in clear cell renal cell carcinoma (ccRCC), sponsored by Kousai Bio. Primary endpoints: Dose-Limiting Toxicity at 28 days and Safety endpoint at 1 year. Planned start Mar 2026; status: withdrawn.
02
Drugs
KSD-201
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06708936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708936.